The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
General Updates | From discovery to decision making: the evolution of MRD at the 13th Miami Myeloma MRD Meeting
Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center & University of Miami, Miami, FL, shares insights into the 13th Miami Myeloma MRD Meeting taking place on April 10th, 2026. Explore the evolution of measurable residual disease (MRD) from early laboratory techniques to a validated predictor of outcomes, and its growing role in drug approval and treatment decision making. This interview took place virtually.
